Friday, July 10, 2026

pharma · Ventilator-Associated Pneumonia · Carcinoma, Squamous Cell

Janssen Research &

Johnson & Johnson is a pharma organization headquartered in CN. Primary therapeutic focus areas include Ventilator-Associated Pneumonia, Carcinoma, Squamous Cell, Erectile Dysfunction, Schizoaffective Disorder, Acute Cor

Raritan, USA HQ
2001 Founded
95 Employees
NMPA registrant Type
Company details
Status
Public
HQ
Raritan, USA
Founded
2001
Employees
95
Programs
7
Drugs
4
Patents
0
Clinical program

Trabectedin

Phase 3 · small molecule · Ovarian Cancer

Trabectedin for Ovarian Cancer is a Phase 3 program (small_molecule) at Johnson & Johnson Pharmaceutical Research & Development, L.L.C. with 1 ClinicalTrials.gov record(s).

Internal code CR003448

Full intelligence profile for this program is being prepared.

At a glance

Sponsor
Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Phase
Phase 3
Modality
small_molecule
Indication
Ovarian Cancer
Status
completed
Trials
1